Literature DB >> 17141138

Prescription naloxone: a novel approach to heroin overdose prevention.

Karl A Sporer1, Alex H Kral.   

Abstract

The mortality and morbidity from heroin overdose have increased in the United States and internationally in the last decade. The lipid solubility allows the rapid deposition of heroin and its metabolites into the central nervous system and accounts for the "rush" experienced by users and for the toxicity. Risk factors for fatal and nonfatal heroin overdoses such as recent abstinence, decreased opiate tolerance, and polydrug use have been identified. Opiate substitution treatment such as methadone or buprenorphine is the only proven method of heroin overdose prevention. Death from a heroin overdose most commonly occurs 1 to 3 hours after injection at home in the company of other people. Numerous communities have taken advantage of this opportunity for treatment by implementing overdose prevention education to active heroin users, as well as prescribing naloxone for home use. Naloxone is a specific opiate antagonist without agonist properties or potential for abuse. It is inexpensive and nonscheduled and readily reverses the respiratory depression and sedation caused by heroin, as well as causing transient withdrawal symptoms. Program implementation considerations, legal ramifications, and research needs for prescription naloxone are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17141138     DOI: 10.1016/j.annemergmed.2006.05.025

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  40 in total

1.  Providing naloxone to substance users for secondary administration to reduce overdose mortality in New York City.

Authors:  Daliah I Heller; Sharon Stancliff
Journal:  Public Health Rep       Date:  2007 May-Jun       Impact factor: 2.792

2.  A response to the opioid overdose epidemic: naloxone nasal spray.

Authors:  Daniel P Wermeling
Journal:  Drug Deliv Transl Res       Date:  2013-02-01       Impact factor: 4.617

Review 3.  Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access.

Authors:  Daniel P Wermeling
Journal:  Ther Adv Drug Saf       Date:  2015-02

4.  Expanding access to naloxone in the United States.

Authors:  Suzanne Doyon; Steven E Aks; Scott Schaeffer
Journal:  J Med Toxicol       Date:  2014-12

5.  Community-Based Response to Fentanyl Overdose Outbreak, San Francisco, 2015.

Authors:  Christopher Rowe; Eliza Wheeler; T Stephen Jones; Clement Yeh; Phillip O Coffin
Journal:  J Urban Health       Date:  2019-02       Impact factor: 3.671

6.  Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.

Authors:  Abby M Bailey; Daniel P Wermeling
Journal:  Ann Pharmacother       Date:  2014-02-12       Impact factor: 3.154

7.  Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program.

Authors:  Christopher Rowe; Glenn-Milo Santos; Eric Vittinghoff; Eliza Wheeler; Peter Davidson; Philip O Coffin
Journal:  Addiction       Date:  2015-08       Impact factor: 6.526

8.  Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administration.

Authors:  Debra Kerr; Paul Dietze; Anne-Maree Kelly; Damien Jolley
Journal:  J Urban Health       Date:  2008-03-18       Impact factor: 3.671

9.  Overdose prevention and naloxone prescription for opioid users in San Francisco.

Authors:  Lauren Enteen; Joanna Bauer; Rachel McLean; Eliza Wheeler; Emalie Huriaux; Alex H Kral; Joshua D Bamberger
Journal:  J Urban Health       Date:  2010-12       Impact factor: 3.671

10.  Can we prevent drug related deaths by training opioid users to recognise and manage overdoses?

Authors:  Romina Lopez Gaston; David Best; Victoria Manning; Ed Day
Journal:  Harm Reduct J       Date:  2009-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.